- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.02. | Pfizer drug acquired in $11B buyout confirms benefit in colon cancer | ||
| 03.02. | Drugmakers prep for bird flu outbreak, despite continued low risk | ||
| 03.02. | Is 2025 the Chinese Year of BioPharma? | ||
| 31.01. | A new, non-opioid pain drug is here. Getting it to patients could be agony. | ||
| 31.01. | Novartis sets 'ambitious' target; Skyrizi, Rinvoq sales climb | ||
| 31.01. | Metsera, Maze Therapeutics secure combined $415 million in IPOs | ||
| 31.01. | Vertex's non-opioid pain drug gets FDA approval in milestone for company and research | ||
| 30.01. | RFK Jr. fumbles Medicare basics during second confirmation hearing | ||
| 30.01. | Christophe Weber, veteran Takeda CEO, to retire next year | ||
| 30.01. | 23andMe considers a sale as cash runs low | ||
| 30.01. | Cargo to drop lead CAR-T therapy, lay off staff after study setback | ||
| 30.01. | RFK Jr. signals he'll back Trump abortion policies, despite prior stance | ||
| 30.01. | Trump administration affirms drug price talks, but will seek input to 'improve' program | ||
| 29.01. | Democrats clash with RFK Jr. over vaccine views at heated Senate hearing | ||
| 29.01. | Judge halts Trump freeze on grants as states report healthcare payment portals back online | ||
| 29.01. | FDA clears use of Ozempic to protect kidney health | ||
| 29.01. | BioAge drops obesity drug; Akero, 89bio cash in on MASH data | ||
| 28.01. | Lawmakers report states shut out of Medicaid payment portals following Trump funding freeze | ||
| 28.01. | Rival radiopharma drug to Novartis' Lutathera succeeds in trial, ITM says | ||
| 28.01. | Enhertu, with new FDA OK, set to supplant chemo in HER2-low breast cancer | ||
| 28.01. | Atalanta banks $97M to send RNAi drugs into the brain | ||
| 28.01. | Versant invests again in obesity, this time backing Helicore Biopharma | ||
| 28.01. | FDA webpages on clinical trial diversity removed after Trump orders | ||
| 27.01. | Sage rebuffs Biogen bid to take it over | ||
| 27.01. | Akero says MASH drug reverses liver damage in study, doubling shares |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
